Anti-RNase L – Purified in vivo GOLD™ Functional Grade

Based on the available search results, clone 2E9 refers to multiple different antibodies targeting various proteins, making it challenging to identify specific in vivo applications in mice for a single clone 2E9. However, the search results provide limited direct information about in vivo mouse applications.

Identified Clone 2E9 Antibodies

The search results reveal several distinct antibodies designated as clone 2E9, each targeting different proteins:

Anti-Amyloid beta A4 protein (APP) - This rat monoclonal antibody detects multiple isoforms of APP and targets an 11 amino acid sequence in the C-terminal region. The antibody shows reactivity with both mouse and human species, though the search results do not describe specific in vivo mouse applications.

Anti-LAT antibody - A mouse monoclonal antibody targeting LAT (Linker for Activation of T cells) validated for immunoprecipitation and Western blot applications. However, no in vivo mouse studies are mentioned in the available information.

Anti-pig SLA Class II DR - This mouse monoclonal antibody recognizes swine leukocyte antigen molecules and inhibits mixed lymphocyte reactions. This antibody is specifically designed for porcine applications rather than mouse studies.

Limitations

The search results do not provide detailed information about common in vivo applications of any clone 2E9 antibody specifically in mouse models. While several clone 2E9 antibodies show mouse species reactivity, the available sources primarily describe in vitro applications such as immunoprecipitation, Western blotting, immunofluorescence, and immunohistochemistry rather than in vivo experimental uses in mice.

In the literature, several antibodies and proteins are commonly used alongside the 2E9 antibody, depending on the specific application and research area. Here are a few examples:

1. Beta Amyloid 2E9 Antibody: This antibody is used for studying Alzheimer's disease, particularly in detecting amyloid-beta plaques in the brain. It is often used in conjunction with other antibodies that target different aspects of Alzheimer's pathology, such as tau proteins.

2. EGFR 2E9 Antibody: This mouse monoclonal antibody targets the epidermal growth factor receptor (EGFR) and is commonly used in flow cytometry and immunocytochemistry for studying cell signaling pathways. It may be used with other antibodies targeting different receptors or proteins involved in cell signaling.

3. Tau 2E9 Antibody: This antibody is used in neuroscience research, particularly for detecting tau proteins associated with neurodegenerative diseases like Alzheimer's. It might be used with other tau antibodies or those targeting amyloid-beta to study neurodegenerative disease mechanisms comprehensively.

4. Secondary Antibodies: In many applications, secondary antibodies like goat anti-mouse IgG or rabbit anti-rat IgG are used to detect primary antibodies such as those labeled "2E9". These secondary antibodies are crucial for various immunological assays, providing a detectable signal through labels like HRP or fluorescent dyes.

In addition to these, proteins like actin or tubulin are often used as loading controls in Western blot experiments to ensure that equal amounts of protein are loaded across different samples.

Commonly Used Proteins for Controls:

• Actin: Often used as a housekeeping protein to verify equal loading in Western blots.
• Tubulin: Another common loading control used to confirm sample integrity and equal protein loading.

These proteins are typically used in various antibody-based assays to validate the effectiveness and specificity of the primary antibodies like the 2E9 series.

Clone 2E9 citations in scientific literature primarily refer to several different monoclonal antibodies, each targeting distinct proteins in diverse research contexts. The main scientific findings relate to antibody specificity, target detection, and their application in disease models and diagnostic assays.

Key findings associated with clone 2E9:

• High specificity and sensitivity for target epitopes:
  For antibodies against phosphorylated TDP-43 (notably pS409/410-TDP-43), clone 2E9 demonstrates strong immunoreactivity and specificity, outperforming several other clones in ELISA, dot blot, and immunohistochemistry tests. This makes 2E9 particularly valuable for detecting pathological TDP-43 inclusions in frontotemporal lobar degeneration (FTLD-TDP) and ALS patient samples.

• Utility in biomarker detection and controversy resolution:
  In the context of 15-keto-cholestane-22-oic acid (15-KA), recombinant antibody RAb2E9 was developed and validated for high-specificity detection in ELISA and confirmed by LC-MS. While sensitive, RAb2E9 was unable to detect 15-KA in EAE mouse serum, helping to clarify controversy over 15-KA as a multiple sclerosis biomarker by showing its undetectability in this context.

• Diagnostic application for glycoprotein-specific antibodies:
  Clone 2E9 developed against glycosylated prostate-specific antigen (fuc-PSA) is highly specific for fucosylated forms, distinguishing them from total PSA. Its reactivity is dependent on both protein and glycan moieties, with no reactivity to deglycosylated PSA, indicating application potential in improved prostate cancer diagnostics by targeting specific glycoforms.

• Other applications and targets:
  Clone 2E9 also appears as a monoclonal antibody for various proteins in commercial reagent catalogs, such as PPP1R2 (protein phosphatase 1 inhibitor 2), RNase L, and pig SLA class II DR for immunoprecipitation, emphasizing its recurrent use as a designation for well-characterized, target-specific monoclonal antibodies in both research and clinical assays.

Summary table of notable clone 2E9 citations:

When referencing "clone 2E9" in literature, check the specific target and context, as the designation is reused across distinct antibodies for different proteins. Citations consistently report high specificity and reliable detection within their validated applications.

The dosing regimens of clone 2E9 across different mouse models are not comprehensively detailed in available literature or dosing guides, and clone 2E9 is associated with several different targets depending on context (e.g., anti-SLA DR in pigs, anti-Tau in neurobiology, anti-beta amyloid). No authoritative dosing recommendations for clone 2E9 in mouse models are explicitly listed in the standard antibody dosing guides for in vivo studies.

Available context and related antibodies suggest the following principles:

• If clone 2E9 is being used as an in vivo depleting monoclonal antibody (mAb) in mouse models, the typical dose range for mAbs with similar applications (e.g., anti-CD4 GK1.5, anti-CD8 2.43, anti-Gr-1 RB6-8C5) is usually 100–250 μg per mouse, delivered via intraperitoneal injection, with dosing intervals of every 2–4 days or 2–3 times per week.

• For antibodies targeting T cell subsets, checkpoint blockade, or depletion (such as anti-CD4, anti-CD8, anti-CTLA-4, anti-PD-1), dosing regimens are chosen based on the desired immunological effect, model specifics (tumor vs infection vs autoimmunity), and antibody isotype, frequently within the above dose and schedule range.

• If clone 2E9 is used for in vitro experiments (e.g., immunohistochemistry, flow cytometry), working concentrations are generally specified based on the application—for example, 1:1,000–1:2,000 dilution for immunohistochemistry or Western blot. These concentrations do not translate directly to in vivo dosing.

• Regimen variation by mouse model is generally dictated by:

  • The disease model or immunological context (e.g., tumor, infection, transplantation).
  • The intended antibody effect (blockade vs depletion vs neutralization).
  • Mouse strain, age, and weight, although fixed dosing is frequently employed for monoclonal antibodies due to their wide therapeutic windows and target specificity.

• Lack of direct published examples: No specific dosing schedules for clone 2E9 in mouse models could be identified in authoritative sources. If clone 2E9 is newly generated for a particular application or target, dosing should start with pilot titration studies using the above reference range for mAbs.

Summary Table: Reference Dosing for Mouse Monoclonal Antibodies in Vivo

If you have a specific application, target, or disease model for clone 2E9, providing those details may allow for more tailored guidance. In summary, use established dosing regimens for similar monoclonal antibodies as a starting point until model-specific data for clone 2E9 is published.